LifeBridge 10000 Successfully Kicks off a New Type of Crowdfunding Campaign

Orlando, Fla. (November 7, 2017) – As LifeBridge 10000 develops its new and innovative technology to destroy stage 4 cancer tumors, the public is responding.

This week, the company picked up 21 investors and a total of 67 potential investors following their campaign in its first small public offering through a unique form of crowdfunding that sells ownership in the company. What’s new about this form of small online public offering is that small investors can sell their shares on the same crowdfunding site 1 year after purchase.

Previously small investors would have to wait for a company to be sold before realizing a potential profit. LifeBridge 10000 is one of the first companies in the country to take advantage of this format which was just announced in September of this year. “It’s like having the benefits of a major public offering without the red tape and expense” said Peter Travers the company’s CEO.

“Investors often find it difficult to invest in companies who are structured to automatically give back a percentage of their profits to those who need assistance,” says Travers. “That said, using this unique form of investing, which relies on social interaction and participation, is attracting the right form of investors who look at the greater good.”

LifeBridge 10000 is developing a next generation of technology to work with tumor treating fields designed specifically for the late stage cancer patient with disease in multiple locations, such as the lung and liver simultaneously. The need for this technology was first discovered when Travers helped his wife Laurie in her fight with stage 4 breast cancer.

During that fight, Travers formed a team of senior engineers that produced a device to mimic a therapy already approved by the FDA for brain cancer, but not yet approved for other types of cancer. The device showed great results in completely resolving severe cancer in the pleura around Laurie’s lungs in just 9 weeks.

However, as the cancer spread, the device the team developed could not handle cancer in 2 or more locations like the lung and liver simultaneously. This forced Travers and his wife to make the excruciating decision as to what cancer to treat and which to let grow. This was the beginning of the end for Laurie and she passed away in 2016. Laurie received nearly 3 extra years of high quality life by wearing the device for over 10,000 hours, mostly during sleep for nearly that entire time.

Because of the limited scope of the present form of Tumor Treating Fields, Travers with his team developed a new form of the therapy built from the ground up for patients like Laurie, fighting wide spread disease. The device is patent pending in 36 countries. The first EU country to finish a patent review was Luxembourg who awarded the company a full 20 year patent. The company just received a Notice Of Allowance from the U.S patent office and its expects the U.S. patent to issue in December of this year.

“Every day, this device could give 404 Americans extended high quality life by eliminating or reducing tumors ravaging their bodies as the therapy has shown minimal to no side effects,” he says. “We’re working diligently to bring this to market as soon as we possibly can and the acceptance and reaction of the crowdfunding community has been heartwarming.”

LifeBridge 10000’s campaign is seeking to raise $100,000 by December 28 2017. Investors are encouraged to click here to invest.

#  #  #

For more information media should contact –

Peter Travers, LifeBridge 10000, 407-416-1099,

Rafael Caamano, UCF Business Incubation Program, 407-408-4297 ,

Alan Byrd, Alan Byrd & Associates, 407-415-8470,

About LifeBridge 10000: LifeBridge 10000 LLC was founded in February of 2015 by a marketing professional, a private investor, and two senior engineers. The company is headquartered in Longwood, FL and has been accepted into the University of Central Florida Business Incubation program, in Winter Springs, as a full participant.

The managing member, Mr. Travers, and his late wife, Laurie, were immersed in the culture of cancer for almost 18 years, which led to the work with TTF (Tumor Treating Fields) technology. Laurie’s Breast Cancer was discovered as stage 3, progressing to stage 4 within the first year. She experienced 12 reoccurrences, 9 rounds of chemotherapy, four series of radiation treatments, thoracentesis to remove fluid from the pleura around her lung 9 times, and participation in two clinical trials.    Treatment with TTF extended Laurie’s life an additional 3 years. Improvement and stability only occurred where Laurie used TTF.

LifeBridge 10000 was founded because of this experience. The objective of the Company is to extend and improve the quality of life for patients with advanced stage cancer by providing a 4th treatment option with their TTF System called the LB10000.  The LifeBridge LB10000 offers the hope of extended survival, improved quality of life, and freedom from the toxic side effects of chemotherapy or radiation. Patients with late stage cancer often do not survive long enough to try new breakthrough treatments.

About the UCF Business Incubation Program:

The University of Central Florida Business Incubation Program is a community resource that provides early-stage companies with the tools, training and infrastructure to become financially stable, high growth/impact enterprises. Since 1999, this award-winning program has helped more than 390 local startup companies reach their potential faster by providing vital business development resources.

With seven facilities throughout the region, the UCF Business Incubation Program is an economic development partnership between the University of Central Florida, the Corridor, Orange, Osceola, Seminole and Volusia counties, and the cities of Apopka, Kissimmee, Orlando and Winter Springs.  For the 2014/15 and 2015/16 fiscal years, the activities of these participating firms have helped sustain more than 4,710 local jobs and have had a cumulative impact of more than $725 million on regional GDP and more than $1.3 billion on regional sales. During the same period, the program has returned $7.41 for every $1 invested in the program. For more information, visit